# Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

> **NCT04557449** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 362 (actual)

## Conditions studied

- Liposarcoma
- Prostate Cancer
- Breast Neoplasms
- Adenocarcinoma of Lung

## Interventions

- **DRUG:** PF-07220060
- **COMBINATION_PRODUCT:** Letrozole
- **COMBINATION_PRODUCT:** Fulvestrant
- **DRUG:** Midazolam
- **COMBINATION_PRODUCT:** Enzalutamide

## Key facts

- **NCT ID:** NCT04557449
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-23
- **Primary completion:** 2026-09-23
- **Final completion:** 2027-11-23
- **Target enrollment:** 362 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04557449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04557449, "Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04557449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*